Thursday, April 23, 2015

The Law of Compounding Medications And Drugs: Pet owners turning to online or veterinary pharmac...

The Law of Compounding Medications And Drugs: Pet owners turning to online or veterinary pharmac...: Veterinarians are too expensive, and it puts pets at risk April 23, 2015 2:03 PM by Peter Fenton

International Scheduling of Ketamine: Why the AVMA needs to be involved in international veterinary medicine

International Scheduling of Ketamine: Why the AVMA needs to be involved in international veterinary medicine

The Law of Compounding Medications And Drugs: AVMA Board of Directors Recommends Policy for Vete...

The Law of Compounding Medications And Drugs: AVMA Board of Directors Recommends Policy for Vete...: Veterinary Pharmacology Education for Pharmacists: the proposed new policy address the ever-increasing concerns that the AVMA has recei...

Laboratories: Drug Testing More Challenging

Laboratories: Drug Testing More Challenging

Methamphetamine Positive Lands Gorder 14-Month Suspension | Paulick Report – Thoroughbred Horse Racing News

Methamphetamine Positive Lands Gorder 14-Month Suspension | Paulick Report – Thoroughbred Horse Racing News

FDA warns veterinarians, pet owners about unsafe pharmaceutical products

FDA warns veterinarians, pet owners about unsafe pharmaceutical products

Thursday, April 2, 2015

Patheon Closes Acquisition of IRIX Pharmaceuticals .

  1. Patheon Closes Acquisition of IRIX Pharmaceuticals ...

    www.pharmaceutical-technology.com/.../pressacquisition-irix-pharmaceu...
    23 hours ago - Patheon has closed the acquisition of IRIX Pharmaceuticals, a company that specialises in making difficult to manufacture active pharmaceutical ingredients ...

GNC agrees to reforms for herbal supplements; it will perform DNA barcoding

After A Cease And Desist Letter, GNC Agrees To Herbal ...

Science 2.0-3 hours ago
... GNC will perform DNA barcoding on the “active” plant ingredientsused in its products ... Josh Bloom, Ph.D., Director of Chemical andPharmaceutical Science, ...
GNC Agrees To Reforms For Herbal Supplements
Science Codex-4 hours ago
Explore in depth (148 more articles)

Essendon doping saga refuses to die as focus finally turns back to ...

Essendon doping saga refuses to die as focus finally turns back to ...

The Guardian-2 hours ago
Dank, who is accused of multiple counts of breaching anti-dopingrules but ... “It is completely unprecedented in international anti-doping for an anti-doping ...
Doping scandal 'overblown': Abbott
NEWS.com.au-22 hours ago
Greens call for ASADA inquiry
Yahoo7 News-22 hours ago
Senior Dons players questioned jabs
International-Herald Sun-10 hours ago



Explore in depth (23 more articles)

Essendon ready to move on and bury hatchet with AFL ove

Essendon ready to move on and bury hatchet with AFL over ...

Herald Sun-22 hours ago
... but I reckon if you keep whipping a (dead) horse you're going to go nowhere. .... The Australian Sports Anti-Doping Authority has until later this month to ...

Office of Inspector General Launches Meaningful Use Audits

Office of Inspector General Launches Meaningful Use Audits
Medscape-34 minutes ago
In healthcare parlance, that typically means 5% or more of a sample. White stated that OIG is ... Most are due not to fraud, but to ignorance. Physicians just don't ...

Robert L. Carter, 74, an oncologist who ran a clinic in Joplin, MO, pleaded guilty this week to buying and selling misbranded prescription drugs. Carter also paid about $972,000 in restitution today to Medicare, Tri-Care, Medicaid programs, which he charged for the drugs, and has agreed to forfeit $1.2 million. He also faces up to a year in federal prison and a fine of up to $100,000.

The FDA has rolled up yet another doctor in its campaign to punish practitioners who knowingly bought unapproved foreign drugs on the cheap, taking the risk of giving patients ineffective or even counterfeit medications, which some of them ended up doing. continue to read Fierce Pharma Manufacturing

FDA opening investigation into permanent birth control device

FDA opening investigation into permanent birth control device ...

WXYZ-2 hours ago
The 7 Investigators have been reporting on a range of healthproblems associated with Essure ... of the device, Conceptus, Inc., perpetrated fraud during the clinical trials, violated the terms of the ... Bayer Healthcare bought Conceptus in 2013.

Feds expand Universal Health Services fraud investigation

Feds expand Universal Health Services fraud investigation to ...

Healthcare Dive-9 hours ago
After years of investigating individual Universal Health Services facilities for alleged Medicare and Medicaid billing fraud, the US Department of Justice has

Accidental pet exposures to hormones: purveyors respond Reactions range from nonchalance to concern

High Importance: Human and Veterinary Drugs! FDA alerts health care professionals and patients not to use products from the Prescription Center pharmacy in Fayetteville, N.C.

FDA alerts health care professionals and patients not to use products from the Prescription Center pharmacy in Fayetteville, N.C.

For Immediate Release

April 2, 2015

Release

The U.S. Food and Drug Administration is joining the North Carolina Board of Pharmacy (NC BOP) to urge health care professionals, including veterinarians, and patients not to use products made and distributed by the Prescription Center pharmacy, located at 915 Hay St., Fayetteville, North Carolina.
In an inspection conducted in March by the NC BOP, state inspectors observed significant deficiencies that raise concerns about the company’s ability to assure the sterility, stability and potency of the sterile and non-sterile human and veterinary drug products that it produced. The Prescription Center has been closed by order of the NC BOP, and the NC BOP has ordered a recall of all lots of sterile and non-sterile products compounded or repackaged and distributed by the Prescription Center between Sept. 10, 2014, and March 10, 2015.

Wednesday, April 1, 2015

CVM Updates FDA Announces Pending Withdrawal of Approval of Nitarsone

CVM Updates FDA Announces Pending Withdrawal of Approval of Nitarsone

FDA issues final guidance on the evaluation and labeling of abuse-deterrent opioids For Immediate Release April 1, 2015

15

Release

The U.S. Food and Drug Administration today issued a final guidance to assist industry in developing opioid drug products with potentially abuse-deterrent properties.
Opioid drugs provide significant benefit for patients when used properly; however opioids also carry a risk of misuse, abuse and death. To combat opioid misuse and abuse, the FDA is encouraging manufacturers to develop abuse-deterrent drugs that work correctly when taken as prescribed, but, for example, may be formulated in such a way that deters misuse and abuse, including making it difficult to snort or inject the drug for a more intense high. While drugs with abuse-deterrent properties are not “abuse-proof,” the FDA sees this guidance as an important step toward balancing appropriate access to opioids for patients with pain with the importance of reducing opioid misuse and abuse.
The document “Guidance for Industry: Abuse-Deterrent Opioids – Evaluation and Labeling” explains the FDA’s current thinking about the studies that should be conducted to demonstrate that a given formulation has abuse-deterrent properties. It also makes recommendations about how those studies should be performed and evaluated, and discusses what labeling claims may be approved based on the results of those studies.
“The science of abuse-deterrent medication is rapidly evolving, and the FDA is eager to engage with manufacturers to help make these medications available to patients who need them,” said FDA Commissioner Margaret A. Hamburg, M.D. “We feel this is a key part of combating opioid abuse. We have to work hard with industry to support the development of new formulations that are difficult to abuse but are effective and available when needed.”

FDA Announces Strategy for Review of Animal Food Ingredients, With Uncertain Implications for Industry By Ricardo Carvajal & Diane B. McColl –March 31, 2015